temozolomide has been researched along with Medulloblastoma in 36 studies
Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report results of a phase I/II evaluating vismodegib + temozolomide (TMZ) in immunohistochemically defined SHH recurrent/refractory adult medulloblastoma." | 9.41 | MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. ( Barritault, M; Bidaux, AS; Bonneville-Levard, A; Chinot, O; Frappaz, D; Garin, G; Hottinger, AF; Laigle-Donadey, F; Le Rhun, E; Meyronnet, D; Montané, L; Pérol, D, 2021) |
| "The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and in combination with temozolomide (TMZ) in pediatric patients with refractory or recurrent neuroblastoma or medulloblastoma." | 9.22 | A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. ( Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016) |
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 9.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma." | 9.17 | Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. ( Aerts, I; Bailey, S; Breazna, A; Cañete, A; Cisar, L; de Toledo Codina, JS; Dorman, A; Estlin, E; Geoerger, B; Gesner, L; Grill, J; Grundy, RG; Hargrave, D; Leblond, P; Madero, L; Nicolin, G; Perek, D; Verlooy, J, 2013) |
| " In this study, we utilized severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma to study the effect of HNG in Temozolomide (TMZ) induced male germ cell apoptosis and white blood cell (WBC) suppression." | 7.91 | The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma. ( Dai-Ju, J; Jia, Y; Lasky, JL; Lue, Y; Panosyan, EH; Swerdloff, RS; Wang, C, 2019) |
| "We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide." | 7.79 | Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013) |
| "Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour." | 7.76 | Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. ( Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA, 2010) |
| " We report results of a phase I/II evaluating vismodegib + temozolomide (TMZ) in immunohistochemically defined SHH recurrent/refractory adult medulloblastoma." | 5.41 | MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. ( Barritault, M; Bidaux, AS; Bonneville-Levard, A; Chinot, O; Frappaz, D; Garin, G; Hottinger, AF; Laigle-Donadey, F; Le Rhun, E; Meyronnet, D; Montané, L; Pérol, D, 2021) |
| "Treatment with temozolomide resulted in relief of clinical symptoms and stabilization of tumour growth for 8 months." | 5.34 | Metastatic medulloblastoma in an adult; treatment with temozolomide. ( Bernsen, HJ; Poelen, J; Prick, MJ, 2007) |
| "Temozolomide is an oral cytotoxic agent that has demonstrated its interest in high grade glioma tumors." | 5.34 | Temozolomide treatment of an adult with a relapsing medulloblastoma. ( Bay, JO; Durando, X; Gilliot, O; Irthum, B; Thivat, E; Verrelle, P; Vincent, C, 2007) |
| "The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and in combination with temozolomide (TMZ) in pediatric patients with refractory or recurrent neuroblastoma or medulloblastoma." | 5.22 | A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. ( Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016) |
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 5.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma." | 5.17 | Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. ( Aerts, I; Bailey, S; Breazna, A; Cañete, A; Cisar, L; de Toledo Codina, JS; Dorman, A; Estlin, E; Geoerger, B; Gesner, L; Grill, J; Grundy, RG; Hargrave, D; Leblond, P; Madero, L; Nicolin, G; Perek, D; Verlooy, J, 2013) |
| "Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy." | 5.12 | Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007) |
| " In this study, we utilized severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma to study the effect of HNG in Temozolomide (TMZ) induced male germ cell apoptosis and white blood cell (WBC) suppression." | 3.91 | The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma. ( Dai-Ju, J; Jia, Y; Lasky, JL; Lue, Y; Panosyan, EH; Swerdloff, RS; Wang, C, 2019) |
| "We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide." | 3.79 | Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013) |
| "We have investigated on the potentiation of etoposide (ETP) and temozolomide (TMZ) cytotoxicity in U-87MG glioblastoma and D283 medulloblastoma cell lines by curcumin (CUR) and turmeric force (TF), a nutraceutical formulation of turmeric, with the objective of assessing the potential for their adjuvant use in brain tumor chemotherapy." | 3.78 | Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines. ( Escalon, E; Melnick, SJ; Nair, SM; Ramachandran, C, 2012) |
| "Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour." | 3.76 | Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. ( Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA, 2010) |
| " The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
| "Methionine depletion causes a demonstrable increase in glutathione levels for medulloblastoma (Daoy) and glioma (D54) cells, with a decrease in MGMT activity for Daoy cells." | 3.75 | Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. ( Estlin, EJ; McGown, A; Najim, N; Podmore, ID, 2009) |
| "In seven MB/PNET cell lines investigated, MGMT promoter methylation was detected only in D425 human MB cells as assayed by the qualitative methylation-specific PCR and the more quantitative pyrosequencing assay." | 1.37 | Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma. ( Arnold, L; Faoro, D; Gerber, NU; Grotzer, MA; Haybaeck, J; Hegi, M; Hürlimann, ML; Mittelbronn, M; Rutkowski, S; Sciuscio, D; Shalaby, T; von Bueren, AO, 2011) |
| "Medulloblastoma is the most common malignant tumor of the central nervous system in children." | 1.37 | The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. ( Lin, F; Lin, J; Rao, J; Sheng, H; Yang, L; Yin, B; Zhang, N; Zhou, H, 2011) |
| "We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years)." | 1.35 | Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. ( Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC, 2009) |
| "Treatment with temozolomide resulted in relief of clinical symptoms and stabilization of tumour growth for 8 months." | 1.34 | Metastatic medulloblastoma in an adult; treatment with temozolomide. ( Bernsen, HJ; Poelen, J; Prick, MJ, 2007) |
| "Temozolomide is an oral cytotoxic agent that has demonstrated its interest in high grade glioma tumors." | 1.34 | Temozolomide treatment of an adult with a relapsing medulloblastoma. ( Bay, JO; Durando, X; Gilliot, O; Irthum, B; Thivat, E; Verrelle, P; Vincent, C, 2007) |
| "Temozolomide is a DNA-methylating agent used in the treatment of malignant gliomas." | 1.33 | Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. ( Ali-Osman, F; Bigner, DD; Cheng, CL; Dolan, ME; Friedman, HS; Johnson, SP; Keir, ST; Li, H; Modrich, P; Quinn, JA; Salzman, AL; Szabo, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (27.78) | 29.6817 |
| 2010's | 24 (66.67) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z | 1 |
| Tian, F | 1 |
| Chen, X | 1 |
| Nitta, RT | 1 |
| Bolin, S | 1 |
| Luo, E | 1 |
| Solow-Codero, DE | 1 |
| Samghabadi, P | 1 |
| Purzner, T | 1 |
| Aujla, PS | 1 |
| Nwagbo, G | 1 |
| Cho, YJ | 1 |
| Li, G | 1 |
| Frappaz, D | 1 |
| Barritault, M | 1 |
| Montané, L | 1 |
| Laigle-Donadey, F | 1 |
| Chinot, O | 2 |
| Le Rhun, E | 1 |
| Bonneville-Levard, A | 1 |
| Hottinger, AF | 1 |
| Meyronnet, D | 1 |
| Bidaux, AS | 1 |
| Garin, G | 1 |
| Pérol, D | 1 |
| Bautista, F | 1 |
| Fioravantti, V | 1 |
| de Rojas, T | 1 |
| Carceller, F | 1 |
| Madero, L | 2 |
| Lassaletta, A | 1 |
| Moreno, L | 1 |
| Jia, Y | 1 |
| Lue, Y | 1 |
| Swerdloff, RS | 1 |
| Lasky, JL | 2 |
| Panosyan, EH | 2 |
| Dai-Ju, J | 1 |
| Wang, C | 1 |
| Massimino, M | 2 |
| Casanova, M | 1 |
| Polastri, D | 1 |
| Biassoni, V | 1 |
| Modena, P | 1 |
| Pecori, E | 1 |
| Schiavello, E | 1 |
| De Pava, MV | 1 |
| Indini, A | 1 |
| Rampini, P | 1 |
| Bauer, D | 1 |
| Catania, S | 1 |
| Podda, M | 1 |
| Gandola, L | 1 |
| Grill, J | 1 |
| Geoerger, B | 1 |
| Gesner, L | 1 |
| Perek, D | 1 |
| Leblond, P | 1 |
| Cañete, A | 1 |
| Aerts, I | 1 |
| de Toledo Codina, JS | 1 |
| Verlooy, J | 1 |
| Estlin, E | 1 |
| Cisar, L | 1 |
| Breazna, A | 1 |
| Dorman, A | 1 |
| Bailey, S | 1 |
| Nicolin, G | 1 |
| Grundy, RG | 2 |
| Hargrave, D | 1 |
| Takeshi, N | 1 |
| Kazuhiko, S | 1 |
| Koji, I | 1 |
| Toshikazu, H | 1 |
| Kaoru, K | 1 |
| Cefalo, G | 1 |
| Ruggiero, A | 2 |
| Barone, G | 1 |
| Ridola, V | 1 |
| Spreafico, F | 1 |
| Potepan, P | 1 |
| Abate, ME | 1 |
| Mascarin, M | 1 |
| Garrè, ML | 1 |
| Perilongo, G | 1 |
| Madon, E | 1 |
| Colosimo, C | 2 |
| Riccardi, R | 2 |
| Wang, Y | 1 |
| Xia, P | 1 |
| Lee, WN | 1 |
| Pak, Y | 1 |
| Laks, DR | 1 |
| Lin, HJ | 1 |
| Moore, TB | 1 |
| Cloughesy, TF | 1 |
| Kornblum, HI | 1 |
| Othman, RT | 1 |
| Kimishi, I | 1 |
| Bradshaw, TD | 1 |
| Storer, LC | 1 |
| Korshunov, A | 1 |
| Pfister, SM | 1 |
| Kerr, ID | 1 |
| Coyle, B | 1 |
| Santos, MC | 1 |
| Silva, PB | 1 |
| Rodini, CO | 1 |
| Furukawa, G | 1 |
| Marco Antonio, DS | 1 |
| Zanotto-Filho, A | 1 |
| Moreira, JC | 1 |
| Okamoto, OK | 1 |
| Mitchell, D | 1 |
| Bergendahl, G | 1 |
| Ferguson, W | 1 |
| Roberts, W | 1 |
| Higgins, T | 1 |
| Ashikaga, T | 1 |
| DeSarno, M | 1 |
| Kaplan, J | 1 |
| Kraveka, J | 1 |
| Eslin, D | 1 |
| Werff, AV | 1 |
| Hanna, GK | 1 |
| Sholler, GL | 1 |
| Pezuk, JA | 1 |
| Valera, ET | 1 |
| Delsin, LE | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Brassesco, MS | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Sandén, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Kool, M | 2 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Bonney, PA | 1 |
| Santucci, JA | 1 |
| Maurer, AJ | 1 |
| Sughrue, ME | 1 |
| McNall-Knapp, RY | 2 |
| Battiste, JD | 1 |
| Wang, CH | 1 |
| Hsu, TR | 1 |
| Wong, TT | 1 |
| Chang, KP | 1 |
| Najim, N | 1 |
| Podmore, ID | 1 |
| McGown, A | 1 |
| Estlin, EJ | 1 |
| Rizzo, D | 1 |
| Attinà, G | 1 |
| Lazzareschi, I | 1 |
| Mastrangelo, S | 1 |
| Maurizi, P | 1 |
| Migliorati, R | 1 |
| Bertolini, P | 1 |
| Pastore, M | 1 |
| Faoro, D | 1 |
| von Bueren, AO | 2 |
| Shalaby, T | 1 |
| Sciuscio, D | 1 |
| Hürlimann, ML | 1 |
| Arnold, L | 1 |
| Gerber, NU | 1 |
| Haybaeck, J | 1 |
| Mittelbronn, M | 1 |
| Rutkowski, S | 2 |
| Hegi, M | 1 |
| Grotzer, MA | 2 |
| Daniel, RA | 1 |
| Rozanska, AL | 1 |
| Mulligan, EA | 1 |
| Drew, Y | 1 |
| Thomas, HD | 1 |
| Castelbuono, DJ | 1 |
| Hostomsky, Z | 1 |
| Plummer, ER | 1 |
| Tweddle, DA | 1 |
| Boddy, AV | 1 |
| Clifford, SC | 1 |
| Curtin, NJ | 1 |
| Aguilera, DG | 1 |
| Goldman, S | 1 |
| Fangusaro, J | 2 |
| Zhou, H | 1 |
| Rao, J | 1 |
| Lin, J | 1 |
| Yin, B | 1 |
| Sheng, H | 1 |
| Lin, F | 1 |
| Zhang, N | 1 |
| Yang, L | 1 |
| Padovani, L | 1 |
| Andre, N | 1 |
| Gentet, JC | 1 |
| Figarella Branger, D | 1 |
| Scavarda, D | 1 |
| Verschuur, A | 1 |
| Cowen, D | 1 |
| Muracciole, X | 1 |
| Sun, P | 1 |
| Liu, Y | 1 |
| Ying, H | 1 |
| Li, S | 1 |
| Ramachandran, C | 1 |
| Nair, SM | 1 |
| Escalon, E | 1 |
| Melnick, SJ | 1 |
| Bacolod, MD | 1 |
| Hagel, C | 1 |
| Heinimann, K | 1 |
| Fedier, A | 1 |
| Kordes, U | 1 |
| Pietsch, T | 1 |
| Koster, J | 1 |
| Friedman, HS | 2 |
| Marra, G | 1 |
| Aguilera, D | 1 |
| Mazewski, C | 2 |
| MacDonald, TJ | 1 |
| Hayes, LL | 1 |
| Kim, S | 1 |
| Castellino, RC | 1 |
| Hongeng, S | 1 |
| Visudtibhan, A | 1 |
| Dhanachai, M | 1 |
| Laothamatus, J | 1 |
| Chiamchanya, S | 1 |
| DeAngelis, LM | 1 |
| Cheng, CL | 1 |
| Johnson, SP | 1 |
| Keir, ST | 1 |
| Quinn, JA | 1 |
| Ali-Osman, F | 1 |
| Szabo, C | 1 |
| Li, H | 1 |
| Salzman, AL | 1 |
| Dolan, ME | 1 |
| Modrich, P | 1 |
| Bigner, DD | 1 |
| Sawamura, Y | 1 |
| Nicholson, HS | 1 |
| Kretschmar, CS | 1 |
| Krailo, M | 1 |
| Bernstein, M | 1 |
| Kadota, R | 1 |
| Fort, D | 1 |
| Friedman, H | 1 |
| Harris, MB | 1 |
| Tedeschi-Blok, N | 1 |
| Sato, J | 1 |
| Reaman, GH | 1 |
| Poelen, J | 1 |
| Bernsen, HJ | 1 |
| Prick, MJ | 1 |
| Durando, X | 1 |
| Thivat, E | 1 |
| Gilliot, O | 1 |
| Irthum, B | 1 |
| Verrelle, P | 1 |
| Vincent, C | 1 |
| Bay, JO | 1 |
| Perry, A | 1 |
| Miller, CR | 1 |
| Gujrati, M | 1 |
| Scheithauer, BW | 1 |
| Zambrano, SC | 1 |
| Jost, SC | 1 |
| Raghavan, R | 1 |
| Qian, J | 1 |
| Cochran, EJ | 1 |
| Huse, JT | 1 |
| Holland, EC | 1 |
| Burger, PC | 1 |
| Rosenblum, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for temozolomide and Medulloblastoma
| Article | Year |
|---|---|
Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neop | 2017 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
7 trials available for temozolomide and Medulloblastoma
| Article | Year |
|---|---|
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; | 2022 |
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Topics: Anilides; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Medulloblastoma; Pyridines; Temozolomide | 2021 |
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cerebellar Neoplasms; Chil | 2013 |
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Child; Child, Preschool; | 2014 |
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz | 2016 |
Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplas | 2010 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
27 other studies available for temozolomide and Medulloblastoma
| Article | Year |
|---|---|
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Casein Kinase II; Enzyme Inhibitors; Humans; Med | 2019 |
The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cerebellar Neoplasms; Human | 2019 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Chemor | 2013 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia | 2014 |
Overcoming multiple drug resistance mechanisms in medulloblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cells, | 2014 |
Embryonic Stem Cell-Related Protein L1TD1 Is Required for Cell Viability, Neurosphere Formation, and Chemoresistance in Medulloblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; | 2015 |
The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Caspases; Cell Line, Tumor; Cel | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebella | 2016 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; C | 2011 |
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Cell Survival; Central | 2010 |
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell | 2011 |
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2011 |
Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Bucladesine; Bystander Effect; Cell Line, Tumor; Cell Survival; Cere | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2012 |
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cerebella | 2012 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Treatment of leptomeningeal relapse of medulloblastoma with temozolomide.
Topics: Brain; Child; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Recurrence; Te | 2002 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2005 |
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Dacarbazine; DNA Repair; Drug Resist | 2005 |
Metastatic medulloblastoma in an adult; treatment with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Magneti | 2007 |
Temozolomide treatment of an adult with a relapsing medulloblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Humans; Magnetic Resona | 2007 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |